Biodegradable Intrascleral Implant of Triamcinolone Acetonide in Experimental Uveitis

Abstract

The biodegradable intrascleral TA implant was found to be effective at suppressing the inflammation induced by experimental uveitis in rabbits for at least 4 weeks.

Novel NSAIDs ophthalmic formulation: Flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect

“…However, in the FBA-EM F2 treated group ( Fig. 8b and d), iris and retina were less disorganized with minimal inflammatory cell infiltration and showed well-preserved architectures (Shin et al, 2009).…”

The Rabbit as an Experimental Model

“…The research utility of the EAU model has largely been replaced by the endotoxin-induced uveitis (EIU) model which is created by intravitreal injection of 10 ng Escherichia coli endotoxin (Allen et al, 1998). An alternative model is created using two subcutaneous injections, 1 week apart with Mycobacterium tuberculosis H37Ra antigen, which creates a severe, non-specific uveitis (Shin et al, 2009). The rabbit model is often used in pre-clinical trials for novel therapeutic strategies such as piroxicam nanoparticles for drug delivery to the eye (Adibkia et al, 2007), the successful use of infliximab as a prophylaxis for recurring uveitis (Diaz-Llopis et al, 2007), and the antiinflammatory properties of topical application of the herbs Curcuma longa and Berberis aristata (Gupta et al, 2008).…”

“…EIU is clinically and histopathologically similar to acute anterior uveitis in humans. This model is being used to develop a biodegradable intrascleral implant of triamcinolone that is proving effective in suppressing the inflammation of uveitis for at least 4 weeks (Shin et al, 2009). The rabbit EIU model is also used to study the role of nitric oxide and peroxynitrite in the pathogenesis of uveitis (Allen et al, 1998).…”

Clinical Review: Update on Treatment of Inflammatory Macular Edema

“…42 The development of biodegradable implants with ME-modifying drugs might become a preferred treatment for uveitic ME in the future. 43,44 The realization of high intraocular levels of anti-inflammatory drugs and avoidance of systemic adverse effects are the major attractive characteristics of intraocular implants. However, atrophy of ocular structures after (repeated) steroid administration as well as diverse intraocular infections might be a hazard of this treatment approach.…”